Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-100 + azenosertib in metastatic colorectal cancer
NL-OMON58618Phase 1Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB-100 and azenosertib in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of dose-limiting toxicities. Started Jun 2024; status: terminated.
02
Drugs
LB-100azenosertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON58618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58618.